95 related articles for article (PubMed ID: 22344701)
1. Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).
Fredenhagen A; Kittelmann M; Oberer L; Kuhn A; Kühnöl J; Délémonté T; Aichholz R; Wang P; Atadja P; Shultz MD
Drug Metab Dispos; 2012 May; 40(5):1041-50. PubMed ID: 22344701
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.
Einolf HJ; Lin W; Won CS; Wang L; Gu H; Chun DY; He H; Mangold JB
Drug Metab Dispos; 2017 Dec; 45(12):1304-1316. PubMed ID: 28912253
[TBL] [Abstract][Full Text] [Related]
3. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer.
Feld R; Woo MM; Leighl N; Shepherd FA; Beck JT; Zhao L; Gazi L; Hengelage T; Porro MG; Nayak A
Cancer Chemother Pharmacol; 2013 Oct; 72(4):747-55. PubMed ID: 24013574
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
[TBL] [Abstract][Full Text] [Related]
5. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
6. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
7. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
Hamberg P; Woo MM; Chen LC; Verweij J; Porro MG; Zhao L; Li W; van der Biessen D; Sharma S; Hengelage T; de Jonge M
Cancer Chemother Pharmacol; 2011 Sep; 68(3):805-13. PubMed ID: 21706316
[TBL] [Abstract][Full Text] [Related]
8. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.
Bonn B; Masimirembwa CM; Castagnoli N
Drug Metab Dispos; 2010 Jan; 38(1):187-99. PubMed ID: 19797609
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.
Srinivas NR
Xenobiotica; 2017 Apr; 47(4):354-368. PubMed ID: 27226420
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
11. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P
Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat for the management of multiple myeloma.
Sivaraj D; Green MM; Gasparetto C
Future Oncol; 2017 Mar; 13(6):477-488. PubMed ID: 27776419
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.
Prince HM; Bishton MJ; Johnstone RW
Future Oncol; 2009 Jun; 5(5):601-12. PubMed ID: 19519200
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
15. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP; Moreau P; San-Miguel JF; Richardson PG
Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
19. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
20. Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
